Latham & Watkins advised Neumora, and Cooley advised the underwriters. Neumora Therapeutics, Inc. announced the pricing of its initial public offering of 14,710,000 shares of its common...
You must be a Standard 1 Year member to access this content.
Cooley advised Oyster Point Pharma on the deal, while Cravath represented Viatris. Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, announced its definitive agreement to be acquired...
You must be a Standard 1 Year member to access this content.
Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...
You must be a Standard 1 Year member to access this content.
Cooley advised Abnormal Security on the deal. Abnormal Security, a leading artificial intelligence-based cloud-native email security platform, announced its $210 million Series C financing round, which...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Pfizer Inc. in the deal, while Cooley represented Arena Pharmaceuticals. Debevoise & Plimpton advised Evercore Group and Guggenheim Securities as financial advisors...
You must be a Standard 1 Year member to access this content.
Cooley LLP advised Engine Biosciences on the deal. Engine Biosciences, a company deciphering complex biology to create medicines, announced its $43 million Series A financing round. Polaris...
You must be a Standard 1 Year member to access this content.
